Clinical Monograph: Oxypro 30 mg (Oxycodone Hydrochloride Extended-Release)

1. Classification and Chemical Overview

Oxycodone is a semi-synthetic phenanthrene-derivative opioid agonist synthesized from the opium alkaloid thebaine. Chemically designated as $(5\alpha ,14\alpha )$-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride. Under the Anatomical Therapeutic Chemical (ATC) system, oxycodone is indexed under N02AA05.

• Product Context: Oxypro is an international brand-name formulation of extended-release oxycodone. The 30 mg strength represents a potent therapeutic unit dose utilized for established chronic pain management in opioid-tolerant or carefully evaluated patients.

• Controlled Status: Strictly regulated as a Prescription Only Medicine (POM) and a Schedule II Controlled Substance (or Class A / Schedule 2 Controlled Drug internationally) due to its extremely high potential for abuse, physical dependence, respiratory depression, and fatal overdose liability.

2. Mechanism of Action and Pharmacodynamics

Oxycodone exerts its primary analgesic and physiological effects through high-affinity interactions with central opioid receptors:

• $\mu$-Opioid Receptor Agonism: Acts as a primary agonist predominantly at $\mu$-opioid ($\text{MOR}$) receptors, and to a lesser extent at $\kappa$ ($\text{KOR}$) receptors in the central nervous system and gastrointestinal tract.

• Hyperpolarization & Inhibition: Activation of $\mu$ receptors inhibits adenylate cyclase, closes voltage-gated calcium channels (reducing presynaptic neurotransmitter release), and opens potassium channels (hyperpolarizing postsynaptic neurons).

• Extended-Release Profile: The modified-release matrix provides a slow, controlled dissolution and absorption profile designed to maintain therapeutic plasma concentrations over a 12-hour dosing interval.

3. Approved Clinical Indications and Dosing Scope

Licensing for oxycodone extended-release includes:

• Severe Chronic Pain: Long-term management of severe chronic pain requiring daily, continuous round-the-clock opioid analgesia when alternative treatment options are inadequate.

Dosing & Administration Regimen:

• Individualized Titration: Dosage must be individualized based on pain severity, prior opioid exposure, and patient age. The 30 mg strength is generally no appropriate as an initial starting dose for opioid-naive patients due to the high risk of profound respiratory depression.

• Tablet Integrity: Extended-release tablets must be swallowed whole. Never crush, chew, split, or dissolve oxypro 30 mg tablets, as tampering destroys the extended-release polymer matrix and causes immediate dose dumping of the entire active drug load, resulting in fatal overdose.

• Dosing Frequency: Administered orally on a fixed schedule, typically every 12 hours.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Biphasic or prolonged absorption profile following oral administration, yielding high oral bioavailability (approximately 60% to 87%) due to lower first-pass metabolism compared to morphine. Peak plasma concentrations occur within 3 to 4 hours for extended-release preparations.

• Distribution: Rapidly distributes into skeletal muscle, liver, intestinal tract, lungs, and cerebrospinal fluid. Plasma protein binding is moderate (~45%). Crosses the blood-brain barrier and placenta.

• Biotransformation: Extensively metabolized in the liver via Cytochrome P450 enzymes (CYP3A4 y CYP2D6):

  • Demethylated via CYP3A4 into noroxycodone (major inactive metabolite).

  • Demethylated via CYP2D6 into oxymorphone (an active metabolite with potent $\mu$-opioid affinity, though present in low plasma concentrations).

• Elimination: Excreted primarily via the kidneys in urine as unchanged drug and inactive conjugates. The terminal elimination half-life of extended-release oxycodone averages 4 to 5 hours (though systemic release continues throughout the 12-hour dosing interval).

5. Physiological Effects and Adverse Event Spectrum

Oxycodone depresses central nervous system functions, suppresses respiratory drive, and inhibits gastrointestinal propulsion.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Constipation, somnolence, dizziness, nausea, vomiting, headache, pruritus, asthenia.

• Common ($\ge 1/100$ to $<1/10$): Dry mouth, abdominal pain, dyspepsia, diarrhea, sweating, anxiety, confusion, insomnia, urinary retention, rash.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Dysphoria, hallucinations, agitation, visual disturbances, bronchospasm, biliary tract spasm, flushing, orthostatic hypotension.

• Rare / Severe (<1/1,000): Severe respiratory depression, apnea, circulatory depression, anaphylactoid reactions, paralytic ileus, toxic megacolon, opioid-induced hyperalgesia, seizures.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindicaciones

• Known hypersensitivity to oxycodone or other phenanthrene alkaloids.

• Acute respiratory depression, severe chronic obstructive pulmonary disease (COPD), or acute asthma attacks.

• Paralytic ileus or suspected surgical acute abdomen.

• Moderate-to-severe hepatic impairment.

• Concurrent administration with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their cessation.

Key Drug Interactions

• CNS Depressants, Alcohol, & Benzodiazepines: Co-administration produces profound, synergistic central nervous system and respiratory depression, significantly elevating the risk of coma and fatal overdose.

• Strong CYP3A4 Inhibitors or Inducers (e.g., Ketoconazole, Macrolide Antibiotics, Rifampicin): Inhibitors can escalate oxycodone plasma concentrations and toxicity risks, whereas inducers can accelerate clearance and reduce analgesic efficacy.

• Serotonergic Agents: Co-administration with other serotonergic medications can increase the risk of serotonin syndrome.

Clinical Precautions and Monitoring

• Boxed Warning (Addiction, Abuse, and Misuse; Life-Threatening Respiratory Depression): Oxypro exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing and monitor all patients regularly. Serious, life-threatening, or fatal respiratory depression can occur.

• Neonatal Opioid Withdrawal Syndrome: Long-term maternal use of oxycodone during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated.